{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:14:48Z","timestamp":1792602888457,"version":"4.5.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Anti-nerve growth factor (NGF) antibodies hold tremendous potential for the management of osteoarthritis pain, but clinical trials have revealed serious adverse effects that are incompletely understood. This review discusses clinical trial results along with preclinical studies that have assessed NGF blockade in experimental osteoarthritis, in order to provide insight for future studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Systematic reviews have revealed that anti-NGF therapy, including tanezumab, is efficacious in improving pain and function, but serious adverse events, including rapidly progressive osteoarthritis and osteonecrosis, resulted in a moratorium on trials that was only recently lifted. Within the past year, preclinical testing has revealed effects of NGF blockade on both pain behaviors and joint structure in experimental models of osteoarthritis. Similar to clinical trial results, these studies in laboratory animals demonstrated analgesic efficacy of NGF blockade. Interestingly, several animal studies have suggested detrimental effects on joint integrity as a result of treatment, particularly when treatment is started early in the disease, when joint damage is mild to moderate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>NGF blockade continues to represent a promising new approach for the treatment of osteoarthritis pain, but the actual benefits and risks remain to be fully elucidated. Preclinical models may suggest patient populations that could be best served while limiting side-effects, but future work should further investigate the mechanisms of benefits and unwanted side-effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000354","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T12:29:28Z","timestamp":1474979368000},"page":"110-118","source":"Crossref","is-referenced-by-count":78,"title":["Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?"],"prefix":"10.1097","volume":"29","author":[{"given":"Rachel E.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Malfait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tcb.2004.05.011","article-title":"Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology","volume":"14","author":"Aloe","year":"2004","journal-title":"Trends Cell Biol"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1523\/JNEUROSCI.13-05-02136.1993","article-title":"Nerve growth factor-induced hyperalgesia in the neonatal and adult rat","volume":"13","author":"Lewin","year":"1993","journal-title":"J Neurosci"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-662-46450-2_4","article-title":"Role of nerve growth factor in pain","volume":"227","author":"Mizumura","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh","year":"2011","journal-title":"Anesthesiology"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.joca.2013.06.004","article-title":"Nerve growth factor: an update on the science and therapy","volume":"21","author":"Seidel","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Lane","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrd4612","article-title":"Drug developers reboot anti-NGF pain programmes","volume":"14","author":"Mullard","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40265-014-0208-6","article-title":"Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?","volume":"74","author":"Bannwarth","year":"2014","journal-title":"Drugs"},{"key":"R10-20230829","first-page":"373","article-title":"Antinerve growth factor in pain management: current evidence","volume":"9","author":"Chang","year":"2016","journal-title":"J Pain Res"},{"issue":"(Suppl 1)","key":"R11-20230829","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.joca.2014.10.003","article-title":"A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee","volume":"23","author":"Schnitzer","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"e0157105","DOI":"10.1371\/journal.pone.0157105","article-title":"Tanezumab for patients with osteoarthritis of the knee: a meta-analysis","volume":"11","author":"Kan","year":"2016","journal-title":"PLoS One"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ijcp.12807","article-title":"Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial","volume":"70","author":"Mayorga","year":"2016","journal-title":"Int J Clin Pract"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","volume":"74","author":"Schnitzer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R15-20230829","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.joca.2015.12.011","article-title":"Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration","volume":"24","author":"Losina","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.joca.2013.06.003","article-title":"A commentary on modelling osteoarthritis pain in small animals","volume":"21","author":"Malfait","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2010.03.002","article-title":"Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain","volume":"149","author":"McNamee","year":"2010","journal-title":"Pain"},{"issue":"(Suppl 2)","key":"R20-20230829","first-page":"A26","article-title":"Efficacy of a novel, locally delivered TrkA inhibitor in preclinical models of OA and joint pain","volume":"23","author":"Flannery","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.joca.2015.05.001","article-title":"Deficits in spontaneous burrowing behavior in the rat bilateral monosodium iodoacetate model of osteoarthritis: an objective measure of pain-related behavior and analgesic efficacy","volume":"23","author":"Bryden","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"R22-20230829","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-208444","article-title":"PKCdelta null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF\/TrkA-induced axonal outgrowth","author":"Kc","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.joca.2015.02.002","article-title":"Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis","volume":"23","author":"Ishikawa","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/annrheumdis-2014-207203","article-title":"Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis","volume":"75","author":"Nwosu","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R25-20230829","article-title":"Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model","author":"LaBranche","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.joca.2016.05.015","article-title":"The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain","volume":"24","author":"Xu","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12917-015-0413-x","article-title":"A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain","volume":"11","author":"Lascelles","year":"2015","journal-title":"BMC Vet Res"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/jvim.13972","article-title":"A feline-specific anti-nerve growth factor antibody improves mobility in cats with degenerative joint disease-associated pain: a pilot proof of concept study","volume":"30","author":"Gruen","year":"2016","journal-title":"J Vet Intern Med"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1526-4637.2012.01478.x","article-title":"Efficacy and safety of intravenous immunoglobulin as adjuvant treatment for refractory neuropathic pain. Results of an open-label, multicenter study","volume":"13","author":"Jann","year":"2012","journal-title":"Pain Med"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"(Suppl 3)","key":"R31-20230829","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.joca.2010.05.030","article-title":"The OARSI histopathology initiative \u2013 recommendations for histological assessments of osteoarthritis in the rat","volume":"18","author":"Gerwin","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0022-5320(71)80086-2","article-title":"Ultrastructural changes in sympathetic neurons of newborn and adult mice treated with nerve growth factor","volume":"36","author":"Angeletti","year":"1971","journal-title":"J Ultrastruct Res"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0006-8993(78)90401-8","article-title":"Biochemical effects of antibodies against nerve growth factor on developing and differentiated sympathetic ganglia","volume":"148","author":"Goedert","year":"1978","journal-title":"Brain Res"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0006-8993(80)90341-8","article-title":"Effects of long-term nerve growth factor deprivation on the nervous system of the adult rat: an experimental autoimmune approach","volume":"198","author":"Gorin","year":"1980","journal-title":"Brain Res"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0006-8993(79)90871-0","article-title":"Immunization of adult rats against 2.5 S NGF: effects on the peripheral sympathetic nervous system","volume":"176","author":"Otten","year":"1979","journal-title":"Brain Res"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2006.063354","article-title":"Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis","volume":"66","author":"Suri","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/rheumatology\/keq188","article-title":"Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis","volume":"49","author":"Walsh","year":"2010","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201701000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:39:25Z","timestamp":1693291165000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201701000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000354","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}